Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04649892 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Predicting Response to Naltrexone With Eye Tracking in Gaming Disorder

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study title revisedv4 See this version in full on ClinicalTrials.gov ↗
  2. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Dec 2023 to Dec 2026 · Start date changed from estimate of Jan 2021 to Jul 1, 2026 · Completion date: Dec 2023 to Jul 2027 · 2 morev3 Show 5 more changesShow less
    • Primary completion date: Dec 2023 to Dec 2026
    • Start date changed from estimate of Jan 2021 to Jul 1, 2026
    • Completion date: Dec 2023 to Jul 2027
    • Interventions: Eye-tracking (Device), Naltrexone (Drug), Placebo (Drug), Psychoeducational (Behavioral) to Eye-tracking (Device), Naltrexone (Drug), Naltrexone group A (Drug), Psychoeducational (Behavioral)
    • Site details revised
  3. Secondary endpoints: details revised at 3 of 10 entries Eligibility criteria expanded, about 5 words · Study description expanded, about 4 wordsv2 Show 2 more changesShow less
    • Eligibility criteria expanded, about 5 words
    • Study description expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
It is a double blind controlled study to test the hypothesis that it's possible to predict the response to naltrexone in Videogame Disorder with the use of Eye Tracking device, during a period of 12 weeks
Trial Details
NCT Number NCT04649892
Lead Sponsor University of Sao Paulo
Conditions Gaming Disorder
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov